Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by GC Cell
04.15.25 -- Regulatory-CMC: A Core Practice For Successful CDMO Partnerships
We know how tough it can be to find the right CDMO, especially when capacity is tight and timelines are critical. That's why we're bringing together 31 CDMOs for our Outsourced Pharma Capacity Update Partners Week — a chance to explore their latest capabilities and available capacity, all from the convenience of your screen. Learn more about our sessions grouped by modality to join us to find the right partner for your project.
A New Paradigm In T-Cell Lymphoma Treatment: CD5 CAR-NK
By Seungryel Han and Miyoung Jung, GC Cell T-cell lymphomas (TCLs) are a rare and aggressive subset of non-Hodgkin lymphomas, accounting for 10–15% of cases. Their incidence is rising, particularly among older adults, intensifying the urgent need for more effective treatment strategies. Standard therapies, such as CHOP-based chemotherapy and hematopoietic stem cell transplantation (HSCT), are often inadequate, resulting in poor response rates, high toxicity, and frequent relapses.
A New Paradigm In T-Cell Lymphoma Treatment: CD5 CAR-NK
By Seungryel Han and Miyoung Jung, GC Cell T-cell lymphomas (TCLs) are a rare and aggressive subset of non-Hodgkin lymphomas, accounting for 10–15% of cases. Their incidence is rising, particularly among older adults, intensifying the urgent need for more effective treatment strategies. Standard therapies, such as CHOP-based chemotherapy and hematopoietic stem cell transplantation (HSCT), are often inadequate, resulting in poor response rates, high toxicity, and frequent relapses.
04.11.25 -- Using Digital Shadows To Reinforce Downstream Modeling
The debate rages on. While the automation that enables continuous processing gets a lot of hype, there are plenty of dyed-in-the-wool biopharma pros who contend that process optimization and intensification yield comparable benefits, without requiring the capital-intensive process overhaul that continuous demands. Join Bioprocess Online Live for a virtual deep dive into the scalability, sustainability, and capital implications of the continuous-versus-optimized debate.
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
YONGIN, South Korea , March 12, 2025 /PRNewswire/ -- GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This "first patient dosing" marks a critical milestone in the company's collaboration with its ex-APAC partner Artiva Biotherapeutics, as we advance the development of this innovative treatment targeting relapsed or refractory NK and T‑cell malignancies.
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
, /PRNewswire/ -- GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This "first patient dosing" marks a critical milestone in the company's collaboration with its ex-APAC partner Artiva Biotherapeutics, as we advance the development of this innovative treatment targeting relapsed or refractory NK and T‑cell malignancies.
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
, /PRNewswire/ -- GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This "first patient dosing" marks a critical milestone in the company's collaboration with its ex-APAC partner Artiva Biotherapeutics, as we advance the development of this innovative treatment targeting relapsed or refractory NK and T‑cell malignancies.
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy News provided by Mar 12, 2025, 7:30 PM ET , /PRNewswire/ -- GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy.
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
Secure transaction. Cancel anytime.
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with GC
Contact GC, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack